Lost Comorbidity of Asthma
Co-Authors: Prof. Wytske Fokkens, Prof. Vibeke Backer, Dr Diego Conti, Mrs Elizabeth Van Staeyen, Prof. Glenis Scadding, Prof. Peter Hellings, Prof. Leif Bjermer, Prof. Milos Jesenak, Prof. Zuzana Diamant, Prof. Susanne Lau.
A EUFOREA comment following the paper on the Epidemiology of Comorbidities and their Association with Asthma Control reflecting data collection from more than 12,000 asthmatic patients in Hungary about their condition, believing in the importance of listing chronic rhinosinusitis (CRS) with or without nasal polyps (CRSwNP or CRSsNP) due to its high incidence and prevalence, its association with asthma which is also endorsed in both GINA and EPOS.
CRS is a prevalent disease imposing a significant health problem that is known to affect up to 10.9% of the global population, while severe CRSwNP is present in approximately 1–2% of the European population. The prevalence of asthma in CRSsNP patients is 21.2%, and 44.9% for CRSwNP patients. Both lead to a significant burden on society in terms of healthcare consumption and productivity loss.